Cost-effectiveness analysis of durvalumab plus etoposide: platinum in the first-line therapy of extensive stage small-cell lung cancer from the Chinese payers' perspective.
Ying-Hui TongHai-Ying DingWen-Xiu XinLi-Ke ZhongGao-Qi XuBo ZhangGuo-Nong YangLuo FangPublished in: Tumori (2021)
The addition of durvalumab to EP chemotherapy is not a cost-effective strategy in the first-line therapy of ES-SCLC from the Chinese payers' perspective.